Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived…
Biotechnology
US, Boston [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Ginkgo Bioworks Holdings, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2021 | - | -7.900 | - | 251 | - | -384 | - | -251 | - | -251 | - | 399 |
| 2022 | -53.8300 | -55.630 | 313 | 471 | -1,830 | -2,704 | -1,806 | -471 | -1,828 | -471 | 862 | 783 |
| 2023 | -50.1500 | -17.600 | 477 | 258 | -2,104 | -892 | -2,059 | -258 | -2,208 | -258 | 1,429 | 430 |
| 2024 | -18.3700 | -10.080 | 251 | 227 | -892 | -491 | -821 | -227 | -864 | -227 | 385 | 378 |
| 2025 | - | -5.810 | - | 203 | - | -308 | - | -203 | - | -203 | - | 339 |
| 2026 | - | 2.F5X/td> | - | 2.F5X/td> | - | 2.F5X/td> | - | 2.F51/td> | - | 2.F51 | - | 2.F51 |
| 2027 | - | 1.F6X/td> | - | 1.F6X/td> | - | 1.F6X/td> | - | 1.F61/td> | - | 1.F61 | - | 1.F61 |
| 2028 | - | 0.F7X/td> | - | 0.F7X/td> | - | 0.F7X/td> | - | 0.F71/td> | - | 0.F71 | - | 0.F71 |